MIST Stock Forecast & Price Target

Milestone Pharmaceuticals is attractive because CARDAMYST is already approved in the U.S. as a self-administered at-home rescue therapy for PSVT, addressing a clear unmet need and offering a compelling alternative to emergency care or delayed oral treatment. The launch is gaining support as commercial coverage has moved from ~25% in 1H26 to >50% today, with ~800 physicians and ~1,500 cumulative prescriptions showing early willingness to try the product, while better reimbursement should improve prescribing depth and revenue quality over time. Beyond PSVT, the China approval adds ex-U.S. optionality through a potentially large 3M-6M diagnosed PSVT market, with up to $98M of additional milestones and tiered royalties of up to 18%, and the ongoing AFib-RVR program offers a much larger long-term upside.

Milestone Pharmaceuticals is viewed negatively because its launch has been softer than expected, with early prescription volume, prescriber productivity, and reported sales failing to validate the ~$250-300M peak PSVT base case. Net revenue per Rx is expected to stay well below $500 through 2026 as most prescriptions rely on copay assistance and GTN runs around ~80%, while commercially covered prescriptions remain a minority despite better economics. The company also faces concentrated dependence on Cardamyst, ongoing operating losses, possible dilution from funding needs, and unresolved regulatory, reimbursement, intellectual-property, and commercialization risks that could limit adoption and keep the commercial opportunity narrower than hoped.